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The pathogenesis of orbital Graves’ disease (GD), a process known as thyroid- 
associated ophthalmopathy (TAO), remains incompletely understood. The thyrotropin 
receptor (TSHR) represents the central autoantigen involved in GD and has been pro-
posed as the thyroid antigen shared with the orbit that could explain the infiltration of 
immune cells into tissues surrounding the eye. Another cell surface protein, insulin-like 
growth factor-I receptor (IGF-IR), has recently been proposed as a second antigen that 
participates in TAO by virtue of its interactions with anti-IGF-IR antibodies generated in 
GD, its apparent physical and functional complex formation with TSHR, and its neces-
sary involvement in TSHR post-receptor signaling. The proposal that IGF-IR is involved 
in TAO has provoked substantial debate. Furthermore, several studies from different 
laboratory groups, each using different experimental models, have yielded conflicting 
results. In this article, we attempt to summarize the biological characteristics of IGF-IR 
and TSHR.  We also review the evidence supporting and refuting the postulate that IGF-IR 
is a self-antigen in GD and that it plays a potentially important role in TAO. The putative 
involvement of IGF-IR in disease pathogenesis carries substantial clinical implications. 
Specifically, blocking this receptor with monoclonal antibodies can dramatically attenu-
ate the induction by TSH and pathogenic antibodies generated in GD of proinflammatory 
genes in cultured orbital fibroblasts and fibrocytes. These cell types appear critical to the 
development of TAO. These observations have led to the conduct of a now-completed 
multicenter therapeutic trial of a fully human monoclonal anti-IGF-IR blocking antibody in 
moderate to severe, active TAO.
Keywords: autoimmune, insulin-like growth factor i receptor, thyrotropin receptor, Graves’ disease, hybrid 
receptor, antibodies, autoantibodies
iNTRODUCTiON
The mechanisms underlying Graves’ disease (GD) remain incompletely understood (1). Among the 
open questions is the basis for loss of immunological tolerance to the thyrotropin receptor (TSHR). 
Factors underpinning the orbital manifestations of GD, a process known as thyroid-associated oph-
thalmopathy (TAO), are even less well understood. The unambiguous identification of a pathogenic 
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autoantigen shared by the orbit and thyroid gland remains to be 
accomplished. TSHR is the most likely candidate by virtue of its 
established central role in mediating the hyperthyroidism associ-
ated with GD. It has been detected, albeit at very low levels, in 
the healthy orbit and at somewhat higher levels in orbital tissues 
during TAO (2). Thyroglobulin (Tg) is another antigen suspect 
because of its previously unexplained presence in the diseased 
orbit (3). The insulin-like growth factor-I receptor (IGF-IR) has 
joined the conversation. It appears to be overexpressed in GD 
in several cellular compartments (4). Insinuation of IGF-IR in 
TAO has ignited substantial debate among workers in the field 
of thyroid autoimmunity (5, 6). In this brief review, we attempt 
to present a balanced assessment of evidence both refuting 
and supporting the concept that IGF-IR plays an active and 
important disease-promoting role in TAO. We also review the 
proposed mechanisms through which the receptor might serve 
as a molecular conduit for transducing disease-related signaling 
initiated by IGF-IR itself and by TSHR. It is possible that IGF-IR 
might be effectively targeted as therapy for TAO.
GeNeRAL CONCePTS ABOUT THe iGF-iR
IGF-IR and the insulin receptor (IR) belong to the family of 
ligand-activated, plasma membrane-bound tyrosine kinase 
receptors. Both receptors are widely expressed in many tissues 
(7). They exhibit substantial structural homology. Depending 
on which regions are compared, they share sequence identities 
varying from 41 to 84% (8). Nevertheless, they serve distinct 
physiological functions in  vivo (9). Because IGF-I and insulin 
can produce the same biological responses, and given the wide-
spread tissue distribution of IGF-IR and IR, it has been difficult 
to determine which of these two receptors mediates a particular 
response (10). Separation of the different physiological functions 
mediated through these receptors in vivo is imposed by several 
factors, including their tissue distribution (9). While IR is primar-
ily involved in metabolic actions, IGF-IR promotes cell survival, 
growth, and differentiation (9). However, IGF-I and insulin can 
interact promiscuously through both receptors, although with 
substantially different affinities (11).
IGF-IR like IR comprises two extracellular α-subunits, each 
containing an IGF-I binding site, and two trans-membrane 
β-subunits where the catalytic determinants for intrinsic 
tyrosine kinase activity are located (7). IGF-I elicits multiple 
biological responses through its high-affinity binding to IGF-IR. 
Transduction of IGF-I-provoked signaling is initiated through 
activation of the intrinsic tyrosine kinase and autophosphoryla-
tion of IGF-IR. This results in the phosphorylation of multiple 
tyrosine-containing downstream substrates, including the IRS 
and Shc proteins (12). Differences in interactions with these sub-
strates arise from the divergent structures of β-subunit and kinase 
domains in IGF-IR and IR. These variations are hypothesized as 
being partially responsible for IGF-I and insulin specificity (13). 
Activated ligand-receptor complexes are thought to be internal-
ized into endosomes (14). Specificity of IGF-I and insulin in vivo 
may result from divergence in the levels of the respective receptors 
in target tissues coordinated with respective ligand concentration 
and availability (15). Hybrid receptors comprising both IGF-IR 
and IR may form in cells expressing both proteins (16). These 
hybrids are formed during the normal posttranslational process-
ing of both receptors (16). Their formation appears to be stochas-
tic and is therefore receptor concentration-dependent (17). They 
also appear to determine relative responsiveness to IGF-I and 
insulin. When levels of IGF-IR exceed those of IRs, IR monomers 
are mainly present as hybrid receptors (17). These hybrids exhibit 
high affinity for IGF-I and thus shift the bias away from insulin 
responsiveness. Although the functional role of hybrid receptors 
remains incompletely understood, studies have demonstrated 
that they behave more like IGF-IRs than IRs (16). IGF-IR can also 
heterodimerize with receptors belonging to other families (18). 
For example, it can form heterodimers with epidermal growth 
factor (19). Inhibition of one constituent of these hybrids can shift 
signaling toward its counterpart receptor (18).
By virtue of its catalytic domain, IGF-IR has traditionally 
been considered a member of the receptor tyrosine kinase fam-
ily. It appears that receptor autophosphorylation, particularly at 
tyrosine residues 1131, 1135, and 1136, is critical to initiation of 
IGF-I-dependent signaling (20, 21). However, this concept of 
IGF-IR activation appears to be oversimplified (22). A revised 
model has now been developed to explain how IGF-I or other 
activating ligands initiate IGF-IR internalization and subsequent 
degradation through lysosomal or proteasomal pathways (23). 
Evidence supports β-arrestins, already implicated in the regula-
tion of G protein-coupled receptors (GPCRs), serving as adaptors 
between the oncoprotein, E3 ubiquitin ligase Mdm2, and IGF-IR 
(24). Mdm2 was originally described as controlling IGF-IR 
ubiquitination and in so doing, promoting its degradation by the 
proteasome system (25). In this manner, β-arrestin-1 acts as a 
crucial component in IGF-IR ubiquitination and downregula-
tion. On the other hand, recent studies provide evidence that 
IGF-IR ubiquitination by β-arrestins/Mdm2 is not simply a 
receptor desensitization system. While down-regulating IGF-IR 
from the cell surface and inhibiting its “classical” kinase signaling, 
β-arrestins activate alternative signaling through MAPK (26). 
The roles played by β-arrestin-1 in IGF-IR resemble its functions 
in regulating the behavior of GPCRs. Thus the protein suppresses 
IGF-IR activity while promoting MAPK signaling (22, 27).
GeNeRAL CONCePTS ABOUT THe TSHR
It has been more than 40 years since convincing evidence was put 
forward for a cell surface-displayed TSHR on thyroid epithelial 
cells (28). The TSHR gene was first cloned by Vassart and col-
leagues in 1989 (29). The encoding mRNA has been detected 
subsequently not only in thyroid tissue but also in multiple fatty 
depots in animals and human beings (30, 31). Its cognate ligand, 
TSH’ is a glycoprotein hormone produced by thyrotrophs located 
in the anterior pituitary gland. TSHR plays a central role in the 
regulation of thyroid growth and function (32). More recently, 
the receptor was co-crystalized with anti-TSHR antibodies and 
its structure solved (33, 34). TSHR belongs to the family of rho-
dopsin-like GPCRs which also includes receptors for luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH). These 
proteins possess seven plasma membrane-spanning regions 
within the so called serpentine domain (35). Surface-displayed 
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TSHR exists as a multimeric structure (36). The extracellular 
region represents the amino-terminus containing a high-affinity 
TSH binding site. The unligated extracellular domain interacts 
as an inverse agonist with the serpentine domain. TSHR is 
encoded by a single gene and is synthesized as a single peptide 
chain that undergoes cleavage into “A” and “B” subunits (37). 
These are then linked by a disulfide bond. Unlike the receptors 
for LH and FSH, the extracellular TSHR domain undergoes 
metalloproteinase-dependent cleavage (38). Some debate exists 
as to whether the cleavage occurs at the same precise site(s) on 
the protein and whether the resulting C-peptide sequence is 
invariant. The specific protease responsible for this cleavage has 
yet to be identified (39). Evidence has been introduced support-
ing the concept that this cleaved receptor fragment is shed and 
provokes the generation of thyroid-stimulating IgGs (TSI) (40). 
Some authors have expressed the view that the cleaved fragments 
of TSHR are released into thyroid lymphatics draining into 
lymph nodes where they are processed by antigen-presenting 
cells through interactions with mannose receptors (38). TSIs are 
responsible for the hyperthyroidism associated with GD (40). But 
not all anti-TSHR antibodies are stimulatory. Some block binding 
of TSH to the receptor (33) while others are viewed as “neutral.” 
The exact mechanisms involved in the activation of TSHR by 
either TSH or TSIs remain uncertain although the ligand bind-
ing epitopes have been localized (33, 34). Interactions between 
the different classes of anti-TSHR antibodies and the receptor 
have also been characterized (41). Signaling downstream from 
TSHR is complex and involves several pathways that cross talk in 
patterns that determine the ultimate genes targeted for activation 
(42–44). Similar but non-identical downstream signaling occurs 
following TSH and TSI binding to TSHR (45).
eXTRA-THYROiDAL TSHR
Detection of TSHR expression peripheral to the thyroid gland 
has implicated the protein in an expanding array of biological 
functions. Particular focus on extra-thyroidal TSHR has involved 
studies examining the pathogenesis of TAO. Feliciello et  al. 
detected TSHR mRNA in orbital tissues from healthy donors 
and those with GD (2). TSH promotes lipolysis in rodents and 
human beings (46, 47). With more advanced techniques of detec-
tion, TSHR has been identified, albeit at a very low level, in many 
fatty and non-adipose tissues (48). The receptor has recently been 
insinuated in the regulation of bone metabolism (49).
eviDeNCe FOR iNTeRACTiONS 
BeTweeN iGF-iR AND TSHR
Accumulating evidence supports the general concept that dis-
similar receptor proteins can interact by forming complex signal-
ing partnerships. Recently, Girnita et al. suggested that IGF-IR 
forms functional hybrids with GPCRs (27). These hybrids utilize 
components of GPCR signaling and can thus activate pathways 
conventionally used by GPCRs (27). Multimeric molecular 
structures of these receptor complexes may help explain the 
functional interplay that appears to occur between IGF-IR and 
TSHR pathways. A relationship between IGF-I and TSH signaling 
was first recognized in 1986 by Ingbar and colleagues (50). They 
demonstrated that IGF-I could either enhance or antagonize the 
actions of TSH in cultured thyroid epithelial cells. For instance, 
IGF-I facilitates the actions of TSH on FRTL-5 cell proliferation 
while attenuating its induction of sodium/iodide symporter, 
interactions mediated through PI3 kinase (51). A synergy between 
the two factors was further demonstrated in the induction of 1, 
2-diacylglycerol production in rat thyroid epithelium. In thyroid, 
the mitogenic activity of IGF-I can be potentiated by TSH (52, 
53). TSH induces IRS-2 monoubiquitination in cultured thyroid 
cells, thereby enhancing IGF-I signaling and mitogenic activity. 
Both TSH and IGF-I enhance the nuclear content of β-catenin 
and thus promote Wnt-dependent thyroid epithelial proliferation 
(54). Conditional knock-out of IGF-IR in thyroid tissue results in 
increased serum TSH levels and lower serum thyroxine concen-
trations (55). This profile of circulating hormones suggests rela-
tive TSHR insensitivity. In contrast, over-expression of IGF-IR in 
thyroid amplifies the action of TSH and exaggerates its impact 
on the synthesis of thyroid hormones (56). We hypothesize that 
a similar potentiating mechanism might apply following TSHR 
stimulation by circulating TSI. Further studies will be required to 
determine whether such a mechanism might underlie the results 
found in some actions of TSI in the pathogenesis of TAO.
It was uncertain how the two pathways might cross talk at 
the target cellular level until Tsui and colleagues reported that 
TSHR and IGF-IR appear to interact directly by forming a protein 
complex (57). Evidence for these TSHR/IGF-IR complexes was 
found in orbital fibroblasts and thyroid epithelium utilizing 
several strategies including co-localization studies with confo-
cal microscopy and co-immunoprecipitation assays. Tsui et  al. 
further demonstrated that a monoclonal blocking antibody 
directed against IGF-IR could attenuate activation of Erk1/2 by 
IGF-I, rhTSH, and IgG from patients with GD (57). This report 
unambiguously demonstrated the functional interdependence of 
TSHR and IGF-IR and strongly suggested that IGF-IR was trans-
activated by TSHR. It was followed by several papers confirming 
(58) and in some cases extending (59, 60) these observations. 
Evidence for bidirectional crosstalk between the two receptors 
was demonstrated in another study in orbital fibroblasts (60). 
IGF-I and TSH were shown to act synergistically in that study 
by inducing HA production in orbital fibroblasts. Another recent 
paper contained evidence that inhibiting PI3 kinase and mTOR 
could attenuate HA accumulation upregulation mediated by 
these receptors (61). Unfortunately, cultures were exposed to the 
small molecule inhibitors for many days, inviting criticism of 
the study design used where conclusions were drawn based on 
findings that may have been non-specific. Another recent report 
demonstrated dependence on TSHR in TSHR knock-out mice of 
IGF-IR protein distribution and levels (62).
eviDeNCe FOR iNvOLveMeNT  
OF iGF-iR iN TAO
Whether a specific autoantigen(s) shared by the orbit and thy-
roid participates in the pathogenesis of TAO remains an open 
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question. To our knowledge, demonstration of antigen-specific T 
cells among those lymphocytes infiltrating the orbit has yet to be 
unambiguously accomplished. One of the earliest investigators to 
explore the issue of an ectopically expressed thyroid antigen in the 
orbit was Kriss (3). He and his colleagues detected Tg in the TAO 
orbit using thyroidolymphography over four decades ago. More 
recent studies have substantiated this earlier work (63). Anti-Tg 
antibodies are commonly detected in thyroid autoimmunity 
including a substantial proportion of those individuals with GD; 
however, it is unclear how Tg or the antibodies directed against 
this protein might play an active role in TAO.
The IGF-I pathway was first implicated in TAO by Weightman 
et al. (64) who detected immunoglobulins in the sera of individu-
als with TAO that could displace binding of radiolabeled IGF-I 
from orbital fibroblast monolayers. This important study was the 
first to question whether antibodies directed against an IGF-I 
binding site might be present in these patients. Later studies from 
Pritchard et  al. (65, 66) reported similar results and identified 
the binding site on orbital fibroblasts as IGF-IR. Their studies 
indicated that GD-IgG and IGF-I recognize a common binding 
site. These later studies also revealed that circulating IgGs in GD 
could induce chemokine expression in TAO orbital fibroblasts, 
indicating that at least some of these antibodies were biologically 
active. Pritchard et al. mapped the critical signaling downstream 
from IGF-IR to the FRAP/mTor/p70S6k pathway. They further 
demonstrated that the induction of IL-16 and RANTES was 
inhibited by rapamycin and by transfecting cells with a dominant 
negative IGF-IR (65, 66). The report also provided evidence for 
IGF-IR over-expression in these cells when compared to the levels 
of the receptor in orbital fibroblasts from healthy tissue.
ARe STiMULATORY ANTi-iGF-iR 
ANTiBODieS DiSTiNCT FROM TSi?
Reports from Pritchard et al. (65, 66) and Smith and Hoa (67) 
suggested that IgGs circulating in patients with GD can activate 
orbital fibroblasts have proven to be controversial (5, 6). The 
debate rests on whether activating antibodies differing from those 
against TSHR (i.e., TSI) and instead directly targeting IGF-IR are 
responsible for the upregulation of cytokine expression and hya-
luronan production in orbital fibroblasts (65–67). A major barrier 
to our quest for the definitive answer derives from an inability 
to distinguish antibodies that activate IGF-IR from those that 
merely bind the receptor but fail to initiate signaling. Among the 
strongest evidence that anti-IGF-IR antibodies are generated in 
GD are the observations of Weightman et al. (64) and Pritchard 
et  al. (65) demonstrating that GD-IgGs displace IGF-I binding 
to orbital fibroblasts. More recently, TSHR A-subunit plasmid 
DNA immunization of mice was shown to result in generation of 
anti-IGF-IR antibodies (68). Those studies were unable to detect 
any additional effects of co-immunization with TSHR and IGF-
1Rα plasmids on the animal phenotype (68). Thus none of these 
reports provides insight into whether the anti-IGF-IR antibod-
ies, distinct from TSI, can activate the receptor. Some workers 
in the field attribute activities of GD-Ig to TSIs rather than IgGs 
targeting IGF-IR; however, subsequent studies by Pritchard et al. 
may provide some guidance (69). They demonstrated similar 
cytokine-inducing activity in synovial fibroblasts from patients 
with rheumatoid arthritis (RA) when challenged by RA-IgG (69). 
Their findings indicate that disease-specific IgGs apart from TSI 
are likely driving these inductions.
More recent studies examining whether activating anti-IGF-
IR antibodies are generated in GD have yielded disparate results. 
Experiments conducted in undifferentiated orbital fibroblasts 
treated with rhTSH or GD-IgG failed to generate increased levels 
of HA (70). In contrast, once differentiated into adipocytes, these 
fibroblasts responded to both (71). Varewijck and colleagues 
(72) have detected activating anti-IGF-IR antibodies in subsets 
of patients with GD. They monitored the phosphorylation of 
multiple tyrosine residues of IGF-IR as the primary read-out for 
assessing IGF-IR activity (72). In contrast, Minich et al. (73) were 
unable to distinguish between low levels of anti-IGF-IR IgG activ-
ity in healthy controls and those with GD. Their assay was limited 
to detecting phosphorylation of a single adjacent pair of tyrosine 
residues (Tyr 1165/1166). They quantified the titer of IGF-IR 
autoantibodies but their assay was incapable of discriminating 
between activating and non-activating antibodies. Furthermore, 
their estimates of the lower limits of antibody titers were based 
on arithmetic arguments rather than on empirical observations. 
Another potentially confounding limitation of their study was 
the likely insensitivity of their assay to low-affinity antibodies. 
Moreover, effects of stimulating antibodies frequently occur 
within a narrow concentration range (74) and their studies did 
not investigate the impact of higher and lower antibody titers. In 
sum, the conclusions drawn by Minich et al. appear to ignore the 
likely complex relationship between circulating antibody titers 
and the magnitude of their biological effects.
Krieger et al. reported an induction by GD-IgG of hyaluronan 
release from orbital fibroblasts despite an absence of IGF-IR 
autophosphorylation (59). The authors argued that this scenario 
rules against an activation of IGF-IR occurring during this 
action of GD-IgG. They concluded that the actions of GD-IgG 
must, therefore, be initiated by TSHR rather than through direct 
interactions with IGF-IR. Yet the authors provided apparently 
contradictory evidence for receptor activation by demonstrat-
ing that the specific IGF-IR tyrosine kinase inhibitor, linsitinib, 
blocks induction by GD-IgG of hyaluronan production. Thus, we 
interpret their findings as strongly suggesting that the Western 
blot assay they used for monitoring IGF-IR phosphorylation 
failed to detect what might have been low-level but physiologi-
cally important receptor activation.
Factors potentially underlying these divergent results include 
the wide array of assays used, differing target cell types, and the 
culture conditions used. With regard to culture media, lot to lot 
variability of endogenous IGF-I, IGF-II, and IGFBP concentra-
tions in the animal sera could alter the background read-out 
activities observed as well as the magnitude of cellular responses. 
Thus, it remains possible although unproven that two discrete 
antibodies generated in GD are at play in the pathogenesis of 
TAO. This theoretical construct involves one antibody directed 
at TSHR and the other at IGF-IR. Antibody-induced receptor 
activation might exhibit tissue specificity. Due to their relatively 
long half-life of greater than 1  week (52), antibody-dependent 
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FiGURe 1 | Theoretical mechanisms involved in the crosstalk between insulin-like growth factor-i receptor (iGF-iR) and thyrotropin receptor (TSHR) 
pathways.  
 (Continued)
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activation of TSHR and IGF-IR could be relatively long-lived. 
It should be stressed that all currently available in vitro systems 
for assessing effects of antibodies on cultured cells may fail to 
mimic conditions existing in vivo. This could result in inaccurate 
estimates of the events occurring in  situ within the orbit and 
potentially in thyroid tissue. In any event, assessment of anti-IGF-
IR antibodies activating pathways conventionally used by GPCRs 
is unprecedented until now.
Most anti-IGF-IR antibodies target the ligand binding site and 
thus block the binding of endogenous ligands, thereby attenuat-
ing receptor activation (52). In contrast, antibodies binding 
elsewhere on the receptor may be more clinically relevant since 
they can induce receptor activation (74). Supporting this general 
concept is the observation that IR-stimulating antibodies activate 
the receptor by cross-linking subunits rather than by reacting 
to specific epitopes (74). Figures  1A–F summarize putative 
mechanisms involved in the pathogenesis of TAO. Agonists acting 
directly at both TSHR and IGF-IR may play roles in stimulating 
signaling pathways downstream from these receptors. Additional 
studies will be necessary to untangle what appear to be complex 
interactions that culminate in the disease.
ULTiMATe TeSTiNG OF THe HYPOTHeSiS 
THAT iGF-iR PARTiCiPATeS iN TAO
Addressing the question of whether IGF-IR plays an important 
pathogenic role in TAO and thereby carries potential for therapeu-
tic targeting must await studies conducted in vivo. That concept 
has been tested very recently in a multicenter, placebo controlled, 
double masked clinical trial of an IGF-IR blocking monoclonal 
antibody (teprotumumab or RV001) in active, moderate to severe 
TAO (http://clinicaltrials.gov/show/NCT01868997). The results 
of that prospective trial should shed new light on this as yet 
unresolved question.
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(A) Binding of TSH-like agonists to TSHR activates the classical post-receptor pathway by inducing cAMP production, resulting in activation of protein kinase A, 
mitogen-activated ERK kinase (MEK), and mitogen-activated protein kinase (MAPK). Phosphorylated MAPK translocates to the nucleus where it stimulates several 
transcription factors regulating gene expression. In this scenario, TSHR activation of its post-receptor pathways is independent of IGF-IR activation.  
(B) Binding of IGF-I-like agonists to IGF-IR activates the classical post-receptor pathway by inducing receptor autophosphorylation leading to activation of the 
phosphoinositide 3-kinase pathway and phosphorylation of Akt. Phosphorylated Akt increases translocation of glucose and is essential for cell survival. Auto-
phosphorylated IGF-IR may also activate Ras which stimulates RAF kinase activity and that of MEK, leading to stimulation of mitogen-activated protein kinase 
(MAPK). Phosphorylated MAPK translocates to the nucleus where it phosphorylates specific transcription factors regulating gene expression. In this scenario, 
stimulation of IGF-IR and its post-receptor pathways is independent of TSHR activation. (C) Bidirectional crosstalk between the two receptors can occur. IGF-IR 
agonists can enhance the effects of TSHR agonists. When IGF-IR agonists bind to IGF-IR and TSHR agonists bind to TSHR, additive/synergistic effects can result in 
higher amplitude stimulation and phosphorylation of MAPK than that resulting from TSHR agonists or IGF-IR agonists acting alone. (D) A specific antibody directly 
targeting IGF-IR might attenuate both IGF-IR- and TSHR-mediated events, thus inhibiting additive/synergistic actions of IGF-IR agonists mediated through TSHR. 
Blocking IGF-IR with an IGF-IR-specific antagonist may be equivalent to its knockdown. This situation is accompanied by relative TSHR insensitivity (55). (e) IGF-IR 
and TSHR appear to form a physical/functional tyrosine kinase/G protein-coupled receptor (RTK/GPCR) hybrid (57). Such hybrids utilize components of GPCR 
signaling and can thus activate conventional pathways used by both receptors. Importantly, IGF-IR stimulation by IGF-IR agonists may lead to non-canonical TSHR 
signaling. Thus, the identical pathways downstream from TSHR may be activated. In this model, signaling downstream from TSHR may occur independently of 
TSHR activation. Thus, functional IGF-IR/TSHR hybrids may result in bidirectional receptor crosstalk. (F) Formation of IGF-IR/TSHR hybrid receptors may underlie 
inhibitory anti-IGF-IR antibody attenuation of actions initiated at both receptors. Thus, blocking IGF-IR may inhibit both IGF-IR and TSHR-mediated effects. This 
situation may carry functional equivalence to knocking down IGF-IR, where relative insensitivity to TSH has been demonstrated (55).
FiGURe 1 | Continued
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